Fidanacogene elaparvovec

DB16783ApprovedInvestigationalGene Therapies

Fidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human coagulation FIX gene that was investigated as a potential treatment for hemophilia B. Hemophilia B is a... Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births worldwide.

Mechanism
Curator reviewed · 2 references
Primary indication
In Canada and the US, fidanacogene elaparvovec is indicated for the treatment of adults (aged 18 years or older) with moderately severe to severe Hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing...Curator reviewed · 10 structured indications
First approval
Canada, 2023 · United States, 2024
Code names
AAV8 HFIX19 · PF-06838435 · SPARK 101 · SPK-9001

Resolves to

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
92Drug interactionsStructured to mechanism, not free text
Sign in
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
10Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
4ContraindicationsEach with its own population and attribute set
Sign in
6Marketed productsAcross 3 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Fidanacogene elaparvovec, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account